Results 251 to 260 of about 67,365 (299)

Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes.

JAMA Netw Open
Xie L, Anazco D, Chancay AH, Mathew MS, Francis JM, Almandoz JP, Messiah SE.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-like peptide-1 receptor action in the vasculature

Peptides, 2019
Glucagon-like peptide-1 receptor (GLP-1R) agonists augment insulin secretion and are thus used clinically to improve glycemia in subjects with type 2 diabetes (T2D). As recent data reveal marked improvements in cardiovascular outcomes in T2D subjects treated with the GLP-1R agonists liraglutide and semaglutide in the LEADER and SUSTAIN-6 clinical ...
Malak Almutairi, Rami Al Batran, John R. Ussher   +2 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists

Surgical Clinics of North America
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +6 more sources

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Lipid effects of glucagon-like peptide 1 receptor analogs

Current Opinion in Lipidology, 2021
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming more prominent as a therapeutic choice in diabetes management and their use is being expanded to other indications, such as obesity. Dyslipidemia and cardiovascular disease are common co-morbidities in these populations and understanding the ...
Amanda J, Berberich, Robert A, Hegele
openaire   +2 more sources

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Sadiya S, Khan, Chiadi E, Ndumele, Dhruv S, Kazi   +2 more
openaire   +2 more sources